Viracta Therapeutics, Inc. (VIRX) Misses Q2 EPS by 3c

Viracta Therapeutics, Inc. (NASDAQ: VIRX) reported Q2 EPS of ($0.32), $0.03 worse than the analyst estimate of ($0.29). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .

For earnings history and earnings-related data on Viracta Therapeutics, Inc. (VIRX) click here.

You May Also Be Interested In

• Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
• Hawaiian Electric trades at 8.8x P/E, but wildfire risk clouds value case
• Karman Space & Defense acquires Walker Precision Engineering